Most diabetic wound care products are passive dressings, only providing a protective barrier against the external environment ...

Amesanar is under clinical development by RHEACELL and currently in Phase II for Diabetic Foot Ulcers. According to GlobalData, Phase II drugs for Diabetic Foot Ulcers does not have sufficient ...

ENERGIF-703 is under clinical development by Energenesis Biomedical and currently in Phase III for Diabetic Foot Ulcers.

Diabetic Foot Disease is defined as a syndrome in which peripheral neuropathy and peripheral vascular disease may result in foot ...

MolecuLight Inc., a global medical device company pioneering point-of-care fluorescence imaging for measuring bacterial load ...

Strategic financing will enable MolecuLight to further accelerate commercialization PITTSBURGH, Jan. 6, 2025 /PRNewswire/ -- ...

TSXV:HEM) Hemostemix Announces the Incorporation of Hemostemix PR Inc: 50% Reimbursement of R&D Expenses in Cash ...